[Sign in] [Register]   

EIAab logo

Index > News Center > News list.
Enter your KeyWord (Ex. ELISA Kit, Cuticular Active Peptide Factor, etc)
Search content in infomation.

Existing Drugs could Benefit Patients with Bone Cancer

Posted by star on 2017-08-29 01:32:07

       New research suggests that patients with bone cancer are likely to respond to IGF1R inhibitors based on their genetic profile. A subgroup of patients with osteosarcoma – a form of bone cancers – could be helped by an existing drug. So far, in the largest genetic sequencing study of osteosarcoma, scientists discovered that 10% patients with a genetic mutation in particular signaling genes about growth factor, may be benefited from existing drugs, known IGF1R inhibitors. The results, published in Nature Communications suggested a re-trial of IGF1R inhibitors for the subset of patients with osteosarcoma could possibly respond within their genetic profile.

      Osteosarcoma is the most common form of primary bone cancers in children and young adults, which is usually from 10 to 24 years old. There are 160 patients firstly being diagnosed with osteosarcoma in the UK each year, in which around one third cannot be cured. The current treatment for osteosarcoma is chemotherapy followed by surgery, without the bone tumor cells being removed. It has been almost 40 years in finding a new treatment for osteosarcoma.

      In the study, scientists analyzed the genome of 112 children and adults with tumors and discovered that 10% of the group had cancer-driving mutations in insulin-like growth factor (IGF) signaling genes. The IGF signaling genes played a major role in bone growth and development during the puberty. And IGF signaling genes were also linked to the uncontrollable growth of bone which is characteristic of osteosarcoma. IGF signaling genes were the target of existing drugs, namely IGF1R inhibitors. In past, the clinical trials by IGF1R inhibitors were also used as the treatment for osteo......


       Nature newly published a research on August 23th that the scientists discovered that additional LAIR1 insertions, as a new insertion modality, would lead to the production of bispecific antibodies against infected erythrocytes of malaria.


           Leukocyte-associated immunoglobulin-like receptor (LAIR1) is a collagen-binding inhibitory receptor encoded on chromosome 19. In previously studies, the scientists inserted the extracellular domain of LAIR1 between the V and DJ segments of an antibody. The antibodies are generated from a single expanded B-cell clone and through the distinct somatic mutations in the LAIR1 domain, could obtain broadly reactive antibodies against RIFINs. As a type of variant antigen expressed on the surface of Plasmodium falciparum-infected erythrocytes, RIFIN provides the pathogen with abundance and variability to escape from host antibodies. Hence, it is the important targets of naturally acquired immunity against malaria.

          To further investigate how frequently such antibodies were produced in response to malaria infection, researchers tested the plasma from two groups of individuals who lived in malaria-endemic regions. They found that that 5–10% of malaria-exposed individuals, except for the European-blood individuals, had high levels of LAIR1-containing antibodies which were acted essentially on infected erythrocytes in febrile malaria, especially characterized additional LAIR1 insertions between the V and DJ segments. By analyzing the antibody-producing B cell clones at the protein level, a second insertion modality which the LAIR1 exon and flanking intronic sequences are insert......

Betatrophin-A New Therapy for Diabetes

Posted by star on 2017-08-18 01:35:23


Diabetes has been one of the most typical diseases now, which could cause clinically high-level of blood sugar, chronic damages and a series of dysfunction in organs, which brings lots of troubles for our lives. However, the effectively therapy is lacking around the world.


 An important target by diabetes effect is pancreatic β-cell, which indicates blood glucose levels and secretes appropriate insulin to regulate glucose and energy homeostasis. Hence, restoration of the functional β-cell mass is potentially a key aim of diabetes therapy.

Based on the previous studies, researchers found that betatrophin, which was encoded by GM6484, could significantly trigger β?cell proliferation to enhance insulin production. Notably, betatrophin transgenic overexpression in liver could accelerate the process, which has been confirmed in mouse with type II diabetes. In addition, betatrophin is a highly-conserved secreted protein in lives of mammalian species, which confirms its suitability in therapeutic approaches

The discovery of betatrophin suggests a newly diabetes therapy. If the discovery is feasible, it will benefit us. Hence, the related mechanism and application remain to be further studied.



2017 BIOtech Japan---- EIAab is coming !

Posted by star on 2017-04-10 22:37:32

After attending the meeting of JACBS in Taiwan and AACR in USA ,we are planning to participate in another grand meeting of BIO industry---2017 BIOtech Japan .EIAab prefer to participate more international cooperation project to Keep learning the latest international research and industry trend ,and then strive to offer the best and update service to our customer !
we would like to invite you to come with us to attend this meeting ,if you do ,contact us freely !

EIAab attend the 32 th JACBS in Taiwan

Posted by star on 2017-03-23 00:26:07

On March 25 to 26 ,The JACBS will be held in Taiwan,We pay highly attention to this meeting and send our staffs to attend it .it is a good chance for us to know the newest information about the bio-tech and will push us to move advance with times!

Page 5 of 72
Hot Genes
ALCAM ACE KSR2 ASPRO C19orf80 Gdf5 Trap1a Atf2
Top Searches
Ubiquitin ELISA Asprosin Ubiquitin-protein ligase metalloproteinase TRAP1A Tumor necrosis vitamin d
Why choose EIAAB
Our products have been quoted by many publications in famous journals such as Cell; Cell Metabolism; Hepatology; Biomaterials.more
Further Information
About us Protein center Bank account Distributors Terms & Conditions Career

Copyright & copy www.eiaab.com2006-2016 All Rights Reserved    EIAab